文献速递系统性红斑狼疮其他结缔组织病

SGLT2抑制剂在风湿免疫病中的心血管结局与安全性:系统综述

Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis.
PubMed 文献 · Semin Arthritis Rheum · 2026-10-22

该系统综述纳入5项研究共11190例风湿免疫病患者(系统性红斑狼疮占70.9%、系统性硬化症占25.4%),评估SGLT2抑制剂的心血管结局与安全性。结果显示SGLT2抑制剂使用与较低的全因死亡率和心力衰竭风险相关,对心肌梗死无明显影响;安全性数据报告不一,以泌尿生殖系统感染最常见。证据主要限于观察性数据且集中于SLE和SSc人群。

要点

  • SGLT2抑制剂在风湿免疫病人群中与较低全因死亡率和心衰风险相关,对心肌梗死无明显影响。
  • 安全性数据报告不一,感染尤其是泌尿生殖系统感染最常被报告。
  • 现有证据主要来自SLE和SSc的观察性研究,住院、停药和疾病活动数据有限且不一致。

核心结论

  • 主要为观察性数据提示SGLT2抑制剂在风湿免疫性IMIDs中可能具有心血管获益,但证据主要限于SLE和SSc人群。
  • SGLT2抑制剂应在2型糖尿病、心力衰竭和慢性肾脏病的既定适应证中使用,仍需在IMID人群开展前瞻性对照研究以确立心血管获益、明确安全性并评估对疾病活动的影响。

研究设计与样本

  • 遵循PRISMA指南的系统综述,检索MEDLINE、Embase、PubMed、Cochrane Library和Web of Science Core Collection数据库(PROSPERO注册号CRD420261289071)。
  • 纳入报告全因死亡率、主要不良心血管事件(MACE)、安全性或IMID疾病活动的成人IMID观察性研究和干预性研究。
  • 共纳入5项研究、11190例IMID参与者,其中系统性硬化症占25.4%、系统性红斑狼疮占70.9%、其他IMIDs占3.9%。

主要发现

  • 在报告MACE的3项研究中,SGLT2抑制剂使用与较低的全因死亡率和心力衰竭风险相关,对心肌梗死无明显影响。
  • 安全性数据报告方式不一,感染尤其是泌尿生殖系统感染最常被报告。
  • 关于住院、治疗中断和IMID疾病发作的证据有限且不一致。

关键数值与推荐

  • 纳入标准为报告全因死亡率、MACE(心血管死亡、心肌梗死、卒中、心力衰竭)、安全性或IMID疾病活动的成人IMID研究。
  • 共纳入5项研究、11190例IMID参与者,SLE占70.9%、SSc占25.4%、其他IMIDs占3.9%。

临床怎么用

  • SGLT2抑制剂应在2型糖尿病、心力衰竭和慢性肾脏病的既定适应证中使用。
  • 在风湿免疫性IMIDs患者中使用SGLT2抑制剂时需关注泌尿生殖系统感染等安全性问题。

局限性

  • 现有证据主要来自观察性研究,且集中于SLE和SSc人群。
  • 安全性数据报告不一,住院、治疗中断和IMID疾病发作相关证据有限且不一致。
  • IMID患者大多被排除在主要临床试验之外,尚需前瞻性对照研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Rheumatic immune-mediated inflammatory diseases (IMIDs) are associated with increased cardiovascular morbidity and mortality. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) improve cardiometabolic outcomes in high-risk populations, but IMID patients were largely excluded from major trials. It remains unclear to what extent these benefits extend to IMIDs. METHODS: Following PRISMA guidance, MEDLINE, Embase, PubMed, Cochrane Library and Web of Science Core Collection databases were searched (PROSPERO: CRD420261289071). Observational and interventional adult IMID studies reporting all cause-mortality, major adverse cardiovascular events (MACE; cardiovascular mortality, myocardial infarction, stroke, heart failure), safety or IMID disease activity with SGLT2i were included. RESULTS: Five studies including 11,190 IMID participants were identified: systemic sclerosis (SSc; 25.4%), systemic lupus erythematosus (SLE; 70.9%) and other IMIDs (3.9%). Across three studies reporting MACE, SGLT2i use was associated with lower all-cause mortality and heart failure risk, with no clear effect on myocardial infarction. Safety data were variably reported, with infections, particularly genitourinary infections, were most frequently reported. Evidence on hospitalisation, treatment discontinuation and IMID flare was limited and inconsistent. CONCLUSION: Predominantly observational data suggest a potential cardiovascular benefit of SGLT2 inhibitors in rheumatic IMIDs, but the available evidence is confined largely to SLE and SSc populations. Whilst SGLT2 inhibitors should be used in established indications of type 2 diabetes mellitus, heart failure and chronic kidney disease, prospective and controlled studies in IMID populations are needed to establish their cardiovascular benefit, clarify safety and evaluate for effect on disease activity.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Gumber L, Scholfield S, Miller CA, et al. Cardiovascular outcomes and safety of SGLT2 inhibitors in rheumatic diseases: a systematic review of evidence predominantly from systemic lupus erythematosus and systemic sclerosis. Semin Arthritis Rheum. 2026. PMID: 42962450. doi:10.1016/j.semarthrit.2026.153090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。